TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29608680
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime
Study: 29608680
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (4 hours) of beta-lactams
Study: 26351780
Drug: LY3023703 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023703 (30 mg)
Study: 26351780
Drug: LY3023703 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023703 (15 mg)
Study: 20129825
Drug: 2 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ng/ml GM‐CSF
Study: 15979009
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMF) treatment for patients <65 years
Study: 12917242
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 1 g meropenem
Study: 12917242
Drug: 3 h
Normalized name: Type 3 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 h infusion of 1 g meropenem
Study: 12917242
Drug: 3 h
Normalized name: Type 3 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 h infusion of 0.5 g meropenem
Study: 10629385
Drug: Dihydroepiandrosterone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroepiandrosterone (50 mg/day)
Study: 2178719
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheet containing Ofloxacin
Study: 2178719
Drug: Ointment-impregnated gauze
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment-impregnated gauze
Study: 7378115
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C (1 NaF tablet with 1 mg F−)
Study: 6427714
Drug: All preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All preparations
Study: 2742729
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg d-amphetamine
Study: 28690028
Drug: Piperacillin/tazobactam (PIPC/TAZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG)
Study: 24942239
Drug: 75% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% sucrose solution
Study: 8974104
Drug: rhGH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.15 mg.kg‐1.d‐1)
Study: 1334821
Drug: Pravastatin (lipid-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (lipid-lowering agent)
Study: 17563161
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (ADM)
Study: 27694216
Drug: Dietary nitrate-rich
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary nitrate-rich beetroot juice (BR), 6.2 mmol of NO3- per shot, seven 70-ml shots consumed during the 48 hours after blood donation.
Study: 27694216
Drug: Placebo (PL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL), seven 70-ml shots consumed during the 48 hours after blood donation.
Study: 20953528
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg intravenous)
Study: 16645152
Drug: Intranasal E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NET (175 microg/275 microg)
Study: 18806686
Drug: Oral E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NET acetate (1 mg/0.5 mg)
Study: 15983301
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and rosiglitazone 4 mg twice daily
Study: 6435371
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and placebo
Study: 15983301
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and rosiglitazone
Study: 14613469
Drug: Glyburide-metformin tablets
Normalized name: glyburide / metformin
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide-metformin tablets
Study: 14613469
Drug: Sulfonylurea plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea plus metformin (SU+Met)
Study: 10877192
Drug: Fructose-1,6-diphosphate (FDP)
DrugBank: Fosfructose (DB13863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose-1,6-diphosphate (FDP) infusion (5 g, 10%)
Study: 10877192
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (5 g)
Study: 8855984
Drug: ondansetron only
Normalized name: Ondansetron only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron only for 5 days after chemotherapy
Study: 8855984
Drug: anti-emetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-emetic treatment with dexamethasone
Study: 1815521
Drug: Piroximone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroximone 25 mg orally
Study: 1815521
Drug: Piroximone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroximone 50 mg orally
Study: 6869204
Drug: Indapamide 5
Normalized name: indapamide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 5 mg once daily for 14 days
Study: 7322956
Drug: Indapamide treatment
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide treatment
Study: 20583949
Drug: Dutogliptin 400
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutogliptin 400 mg once daily for 5 days
Study: 20583949
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily for 5 days
Study: 20583949
Drug: Dutogliptin 400
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutogliptin 400 mg once daily and Metformin 1000 mg twice daily for 5 days
Study: 15919161
Drug: Psychotherapy relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy relapse prevention treatment
Study: 8898763
Drug: Hypertension defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg or current use of antihypertensive medications
Study: 6325994
Drug: sotalol, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol, 320 or 960 mg/day
Study: 19792989
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks
Study: 15475095
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of more than 3 l of crystalloids during abdominal surgery
Study: 15475095
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of more than 500 ml of colloids during abdominal surgery
Study: 7742331
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine 10 micrograms
Study: 7742331
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine 20 micrograms
Study: 21613310
Drug: Mavrilimumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab (1.0 and 3.0 mg/kg)
Study: 15193480
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of l-carnitine (2 g/d) and l-acetyl-carnitine (1 g/d)
Study: 10958260
Drug: Antidepressants (imipramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (imipramine, clomipramine, paroxetine)
Study: 15338100
Drug: Diazepam 2.5
Normalized name: diazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 2.5 mg
Study: 6404954
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg
Study: 6404954
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg
Study: 29952189
Drug: PLF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLF with local bone graft with BM concentrate augmentation (BM group)
Study: 22714033
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin (100 mg suppository)
Study: 22714033
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert suppository)
Study: 20662716
Drug: Replication-defective adenovirus
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replication-defective adenovirus type 5 HIV-1 gag vaccine
Study: 9549819
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment in advanced cancer
Study: 7605708
Drug: Weight-bearing exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-bearing exercise (50 'heel drops' daily and weekly mixed exercise class)
Study: 7605708
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly low-impact exercise class and daily flexibility exercises)
Study: 2178854
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine (single dose)
Study: 2178854
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine (multiple doses, b.i.d. for 7 days)
Study: 24328444
Drug: Quadrivalent influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent influenza vaccine (QIV)
Study: 21998698
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine
Study: 31577041
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) gel treatment for 45 days
Study: 17881751
Drug: Repeat courses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat courses of antenatal corticosteroids (betamethasone, 12 mg intramuscularly, repeated once at 24 hours)
Study: 10841243
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone
Study: 11347790
Drug: Training intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training intervention (14-hour program in seven weekly 2-hour sessions)
Study: 9783563
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (starting at 25 mg/d and increasing to 250 mg/d)
Study: 9783563
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (initially randomized to receive i.v. placebo and treated subsequently with several days of open-label i.v. clomipramine)
Study: 9783563
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (1 month after i.v. infusion)
Study: 7945519
Drug: Ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysinate (IBL) 800 mg/d
Study: 7945519
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 2000 mg/d
Study: 16015665
Drug: Cyproheptadine hydrochloride
Normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine hydrochloride (CH) 4 mg up to four times a day
Study: 10383550
Drug: Bosentan 500
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 500 mg twice daily for 1 week
Study: 10383550
Drug: Digoxin 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.375 mg once daily for 13 days
Study: 1879030
Drug: Tablet cucumber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet cucumber vine compound
Study: 1879030
Drug: Tablet hypotension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet hypotension compound (Control)
Study: 7106164
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg tablets
Study: 29058298
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations
Study: 19540518
Drug: Metoclopramide, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 0.2 mg/kg/dose q 6 hours
Study: 19540518
Drug: Ranitidine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 2 mg/kg/dose q 8 hours
Study: 15385355
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of rocuronium based on real body weight (Group 1)
Study: 11481696
Drug: Idazoxan 20
Normalized name: Idazoxan
DrugBank: Idazoxan (DB12551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan 20 mg
Study: 8110564
Drug: i.v. fluids
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fluids (preloading with normal saline 16 ml kg‐1 and, if necessary, three subsequent boluses of 2.5 ml kg‐1)
Study: 30932170
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg)
Study: 8694322
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%, 40 mL)
Study: 1348167
Drug: Vecuronium repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium repeated injection
Study: 15815895
Drug: Vecuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium infusion
Study: 28391664
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract tablets (0.7 g, 0.05% green tea extract, equivalent to 1 mg polyphenols for three tablets)
Study: 28391664
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (identical to test tablets but without active agent)
Study: 15087592
Drug: Shower PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shower PUVA with trioxsalen (0.27 mg/l) for 10 min
Study: 15087592
Drug: Shower PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shower PUVA with trioxsalen (0.27 mg/l) for 5 min
Study: 9855321
Drug: valspodar 400
Normalized name: VALSPODAR
DrugBank: Valspodar (DB11869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: valspodar 400 mg
Study: 15198411
Drug: dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 8 mg
Study: 9855321
Drug: both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both drugs concomitantly
Study: 7738215
Drug: Intermittent famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent famotidine (20 mg every 12 hr)
Study: 7738215
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cimetidine (1200 mg/24 hr)
Study: 31797570
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded)
Study: 31109838
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy
Study: 15648529
Drug: Parent Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Management Treatment (PMT) in the experimental group (E)
Study: 8513955
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (200 mg) under fasting conditions
Study: 8513955
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (100, 200, or 300 mg) under fasting conditions
Study: 3597168
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg caffeine
Study: 27486873
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment (mean daily dose 11.8 ± 7.0 mg/kg, mean duration 16 months)
Study: 22219335
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg twice daily for 1 week)
Study: 19473822
Drug: Cheese naturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese naturally rich in cis-9, trans-11 CLA (200 g/week)
Study: 15897376
Drug: Conservative acne
Normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative acne therapy
Study: 12849654
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I agents
Study: 18769963
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day for 3 years)
Study: 12675021
Drug: Alendronate (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (any dose)
Study: 7272177
Drug: Caroxazone 200
Normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone 200 mg three times daily
Study: 7272178
Drug: Caroxazone (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone (after discontinuation)
Study: 24140678
Drug: Prasugrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel with low-dose aspirin (<150 mg)
Study: 24140678
Drug: Prasugrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel with high-dose aspirin (≥150 mg)
Study: 21884007
Drug: B-group vitamins
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-group vitamins (folic acid 1 mg, vitamin B12 0.4 mg, and B6 10 mg)
Study: 19538242
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g orally without a SMM (fasting)
Study: 18085140
Drug: Medicine cup
Normalized name: Ezy Dose Kids Medicine Cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine cup group (n = 47) treated with cupping therapy using a self-made medicine cup with 45 degrees C Chinese herb solution.
Study: 8528851
Drug: Rapid i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid i.v. injection of famotidine
Study: 8528851
Drug: Slow i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow i.v. infusion of famotidine
Study: 1778319
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccine (25 micrograms PT)
Study: 1778319
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccine (8 micrograms PT)
Study: 8538704
Drug: Whole-cell DTP
Normalized name: ActHIB with Whole-Cell DTP Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell DTP vaccine
Study: 1778319
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccines (both doses)
Study: 1777371
Drug: Theophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (250 mg)
Study: 7213528
Drug: Aminophylline (390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (390 mg)
Study: 21782507
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab
Study: 17613279
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, orally twice daily with meals for one month)
Study: 9790395
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg rectal misoprostol
Study: 8538974
Drug: Telephone support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone support intervention (weekly calls throughout pregnancy)
Study: 31225625
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content cigarettes (0.4, 2.4, 5.2, 15.8 mg/g)
Study: 30287158
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and olanzapine
Study: 26162521
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TG) 80 mg daily for 4 days
Study: 24284442
Drug: W25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: W25 (25 g whey protein, 3.0 g leucine)
Study: 24284442
Drug: W6 (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: W6 (6.25 g whey protein, 0.75 g leucine)
Study: 24284442
Drug: W6+Low‐Leu (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: W6+Low‐Leu (6.25 g whey protein supplemented to 3.0 g total leucine)
Study: 22871086
Drug: Pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib sodium 0.3 mg intravitreal injection
Study: 18823228
Drug: Tryptophan supplements
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan supplements (3 g per day for 14 days)
Study: 17893438
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/ml, maximum 16 mg) in a single dose
Study: 11684376
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous hormonal replacement therapy (HRT)
Study: 3285878
Drug: Nifedipine 120
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 120 mg/day
Study: 18759767
Drug: PARMA 5
Normalized name: para-phenylenediamine
DrugBank: p-Phenylenediamine (DB14141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARMA 5 computer-assisted dosage
Study: 15522941
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (E2)
Study: 9467549
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2)
Study: 2069221
Drug: Heparin flush
Normalized name: heparin flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flush twice daily
Study: 31666828
Drug: Neostigmine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (1 mg)
Study: 31666828
Drug: Dexmedetomidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (35 μg [0.5 μg/kg])